Announcement • Aug 26
Nuformix plc Announces Board Changes Nuformix plc had announced the appointment of Tim Metcalfe as Non-Executive Chairman and a Director of the Company with effect from September 1, 2026. Julian Gilbert, the Company's current Non-Executive Chairman, had decided to step down from the Board on August 31, 2026 for personal reasons, but he will remain available to the Company in a consultancy capacity, providing continuity and access to his considerable sector knowledge and experience. Tim is a highly experienced corporate financier and company adviser, having spent over 30 years in a variety of senior City and corporate roles. He has held senior positions at Robert Fleming, Rothschild, Westhouse Securities, Northland Capital Partners and he was Joint CEO of Zeus Capital, prior to co-founding IFC Advisory, an investor relations and financial PR adviser, in 2015. During his career, Tim has had a particular focus on advising companies on strategy, M&A, capital markets and regulatory matters. In addition to his role as Managing Director of IFC Advisory, Tim is Senior Independent Non-Executive Director of The Investment Company plc, an investment trust listed on the Main Market of the London Stock Exchange, and Non-Executive Chairman of Equipmake Holdings plc, which is listed on Aquis. He is also a director of a number of private companies. In accordance with UKLR 6.4.8R, Timothy Mark Metcalfe currently holds, or has held during the five years preceding the date of this announcement, the following directorships of publicly quoted companies: Current: Equipmake Holdings plc; The Investment Company plc. Former: Spiritus Mundi plc. New Risk • Mar 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£4.83m market cap, or US$6.42m). Announcement • Mar 18
Nuformix plc has completed a Follow-on Equity Offering in the amount of £1 million. Nuformix plc has completed a Follow-on Equity Offering in the amount of £1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 500,000,000
Price\Range: £0.002
Transaction Features: Subsequent Direct Listing 
